October 2019 – MedAccess and The Bill and Melinda Gates Foundation announced a four-year agreement with global chemical producer BASF to reduce the price of 35 million next generation bednets, the BASF Interceptor® G2. The collaboration is instrumental in speeding up access to a new and innovative mosquito-control technology at lower prices to communities with the greatest needs.
Around the world, every two minutes a child dies from malaria.
There are more than 200 million new cases every year, and almost half a million deaths. Infants, children under five and pregnant women are the most vulnerable groups.
Nowhere is the problem more severe than in Africa with more than 90% of the malaria burden. Beyond loss of life, malaria disrupts education, industries and national economies.
Tackling insecticide resistance and health market barriers.
The disease is preventable and treatable, and in recent years, significant progress has been made. Since 2010, nearly seven million lives have been saved largely due to the distribution of insecticide-treated mosquito nets.
However, the highly-adaptable mosquito has developed resistance to public health insecticides, causing malaria rates to rise after many years of decline. More than 60 countries now report resistance to at least one insecticide class used to combat malaria.
Swift access to the latest medicines and treatments remains a major obstacle for governments tackling diseases such as malaria at scale.
MedAccess’ guarantee enables BASF to better plan long-term resources and reduce the cost of the new nets by an average of 40% over the contract period.
This will make the nets more accessible and affordable for countries where insecticide resistance is growing, and conventional nets are becoming less effective.
The new nets will help to protect the health of millions of people particularly in countries across sub-Saharan Africa, including Burkina Faso, Côte d’Ivoire and Mali.
The agreement is a key achievement for public-private partnership and reflects the commitment of organisations such as the Innovative Vector Control Consortium (IVCC) who partnered with BASF to support the development of the nets. It also supports the objectives of the New Nets Project co-financed by The Global Fund and Unitaid.
What makes the net so special?
BASF’s new mosquito Interceptor® G2 net is based on two insecticides and has been designed specifically to combat resistance in the fight against malaria.
For more than a decade, BASF scientists worked to successfully repurpose alpha-cypermethrin and chlorfenapyr, a completely new insecticide class for public health, for use together on mosquito nets.
The dual-insecticide net received an interim recommendation from the World Health Organisation in 2017 – the first for a product based on a new class of chemistry in more than 30 years.